• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Genzyme

Genzyme

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Studies in Infants and Children With Spinal Muscular Atrophy

    Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Studies in Infants and Children With Spinal Muscular Atrophy

  2. Alnylam Reports Six-Month Clinical Data from Patisiran Phase 2 Open-Label Extension (OLE) Study in Patients with Familial Amyloidotic Polyneuropathy (FAP)

    Alnylam Reports Six-Month Clinical Data from Patisiran Phase 2 Open-Label Extension (OLE) Study in Patients with Familial Amyloidotic Polyneuropathy (FAP)

  3. to-BBB Completes Management Team and Announces Company Name Change to BBB Therapeutics

    to-BBB Completes Management Team and Announces Company Name Change to BBB Therapeutics

  4. Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps

    Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps

  5. REITs, Target Dates, Dollar-Proofing, and More

    A roundup of investment news.

  6. High-Confidence Stock Picks

    Focusing on stocks with the most visible cash flows has been a winning strategy, and this screen can find them.

  7. Early Favorites for Manager of the Year--Domestic Stock

    Who's in front heading 'round the bend?

  8. Pharmaceutical Firms Get the Urge to Merge

    Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.

  9. Back to Basics

    This screen finds stocks that would make it into Morningstar's Wide-Moat Focus strategy.

12
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.